Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +

Not Applicable

Completed

• Conditions: ALCL
• Interventions: Other: Blood sample

• Registration Number: NCT02902874
• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary

To study the correlation between the polymorphism of the main immunity genes and progression-free survival in ALCL of the child.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-04-21
• Study First Submitted: 2016-09-07
• Study First Submitted QC: 2016-09-12
• Study First Posted: 2016-09-16
• Primary Completion: 2020-12-31
• Study Completion: 2020-12-31
• Status Verified: 2022-05
• Last Update Submitted: 2022-05-24
• Last Update Posted: 2022-05-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 185

Inclusion Criteria

• Every patients treated according to COPAD-IGR, HM 89,91 and 97 and ALCL99 protocols and included in related studies
• Clinical data registered in SFCE database
• Signed consent form

Exclusion Criteria

• No ALK expression on tumour
• No consent signed

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients treated for anaplastic large cell lymphoma ( ALCL )	Blood sample	-

Primary Outcome Measures

Name	Time	Method
Number of single nucleotide polymorphisms in main immunogenicity genes using VERACODE ILLUMINA technology	up to 78 months

Trial Locations

Locations (1)

Gustave Roussy; 🇫🇷 Villejuif, Val De Marne, France